Hyperfine Completes Enrollment in Contrast PMR Study for Swoop System Expansion — Hyperfine, Inc.

Event summary

Hyperfine completed enrollment in the Contrast PMR study, evaluating contrast-enhanced imaging with its Swoop® portable MRI system.
The study aims to support an FDA 510(k) submission to expand the Swoop system's indications for use with contrast agents.
Hyperfine plans to submit the FDA application by the end of 2026.
The study was conducted across multiple centers and involved assessing lesion visualization with gadolinium-based contrast agents.

The big picture

Hyperfine's completion of the Contrast PMR study marks a critical step in broadening the clinical applications of its Swoop portable MRI system. Contrast-enhanced imaging is essential for evaluating brain tumors and inflammatory disorders, representing a significant portion of brain MRI examinations. Successful FDA clearance could position Hyperfine to capture a larger share of the point-of-care imaging market, particularly in outpatient and surgical settings. The study's outcomes will be closely watched as they could redefine the role of portable MRI in neurological care.

What we're watching

Regulatory Approval: Whether the FDA will clear the Swoop system for contrast-enhanced imaging by the end of 2026, expanding its clinical utility.
Market Adoption: How contrast-enhanced imaging capabilities will accelerate the adoption of the Swoop system in diverse care settings.
Competitive Positioning: The pace at which Hyperfine can differentiate itself in the portable MRI market with expanded indications.